6533b872fe1ef96bd12d2dd5

RESEARCH PRODUCT

The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis.

Massimiliano AlùLivio BlasiAlessandro RussoTindara FranchinaAntonio RussoClaudia CelesiaGiovanni SortinoVincenzo AdamoAgata LaudaniGiuseppe BronteSergio RizzoFrancesco PassigliaAntonio PiconeGiuseppina Savio

subject

Cancer Researchmedicine.drug_classbusiness.industryWild typePharmacologymedicine.diseaseTyrosine-kinase inhibitorThird generationSecond lineOncologymedicineCancer researchRetrospective analysisNon small cellLung cancerbusinessTyrosine kinase

description

e19030 Background: Second-line treatment for advanced non-small-cell lung cancer (aNSCLC) patients includes monotherapy with a third generation cytotoxic drug (CT) or with the tyrosine kinase inhib...

https://doi.org/10.1200/jco.2015.33.15_suppl.e19030